IMMX
vs
S&P 500
IMMX
S&P 500
Over the past 12 months, IMMX has significantly outperformed S&P 500, delivering a return of +216% compared to the S&P 500's +13% growth.
Stocks Performance
IMMX vs S&P 500
Performance Gap
IMMX vs S&P 500
Performance By Year
IMMX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Immix Biopharma Inc
Glance View
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 2 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the development of therapies for patients with cancer and inflammatory diseases. The company is developing a class of tissue-specific therapeutics (TSTx) in oncology and inflammation. The Company’s lead asset, IMX-110, is is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer controlling tumor micro-environment (TME) normalization technology, which is delivered into the TME. IMX-110, is in clinical trials for solid tumors in the United States and Australia. The Company’s System Multi-Action RegulaTors SMARxT Tissue-Specific platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Its Immune Normalization Technology used for inflammatory bowel disease with GLUT1 antibody biomarker targeting coupled with polyphenol poly-kinase inhibitor.
